Lansoprazole: pharmacokinetics and pharmacodynamics.
Moules
I K
IK
Lederle Laboratories, Gosport, UK.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D007674:Kidney Diseases / Q000378:metabolism; D064747:Lansoprazole; D008107:Liver Diseases / Q000378:metabolism; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D011355:Prodrugs / Q000493:pharmacokinetics*; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D011355:Prodrugs; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole